SCHEMBL13019095

SCHEMBL13019095

Oc1ccc(-c2nc3ncnc(NCCCN4CCOCC4)c3nc2-c2ccc(O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 2/20 0.58
▸ ALDH1A1 P00352 7/20 0.48
▸ USP2 O75604 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 6/20 0.46
▸ MAPT P10636 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ ADK P55263 2/20 0.45
▸ TP53 P04637 3/20 0.45
▸ POLB P06746 1/20 0.45
▸ RAD52 P43351 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ IDE P14735 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3735080 0.78 FGFR1 (0.51) PIK3CGALDH1A1USP2TSHRMEN1
SCHEMBL12330655 0.73 TLR9 (0.67) PIK3CGALDH1A1USP2TSHRMEN1
SCHEMBL12330716 0.72 TLR9 (0.66) ALDH1A1USP2TSHRMEN1KMT2A
SCHEMBL3510105 0.68 ALDH1A1 (0.50) PIK3CGALDH1A1USP2TSHRMEN1
SCHEMBL14544922 0.67 MAPT (0.53) ALDH1A1USP2TSHRMEN1KMT2A
SCHEMBL2478712 0.66 LMNA (0.47) ALDH1A1USP2TSHRMEN1KMT2A
SCHEMBL4692325 0.66 FYN (0.58) —
SCHEMBL3504380 0.65 ALDH1A1 (0.48) PIK3CGALDH1A1USP2TSHRMEN1
SCHEMBL13472316 0.65 ALDH1A1 (0.52) ALDH1A1USP2TSHRMEN1KMT2A
SCHEMBL14983476 0.65 PIK3CG (0.71) PIK3CGALDH1A1USP2TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100330030-A1 Vasculostatic Agents and Methods of Use Thereof TARGEGEN, INC. (US) 2010-12-30 — — US disclosed
US-20100330030-A1 Vasculostatic Agents and Methods of Use Thereof TARGEGEN, INC. (US) 2010-12-30 — — US disclosed
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF TARGEGEN INC. 2010-11-04 — — US disclosed
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF TARGEGEN INC. 2010-11-04 — — US disclosed
US-20070208019-A1 Vasculostatic agents and methods of use thereof TARGEGEN, INC. 2007-09-06 — — US disclosed
US-20070208019-A1 Vasculostatic agents and methods of use thereof TARGEGEN, INC. 2007-09-06 — — US disclosed
US-7208493-B2 Vasculostatic agents and methods of use thereof TARGEGEN, INC. (US) 2007-04-24 — — US disclosed
US-7208493-B2 Vasculostatic agents and methods of use thereof TARGEGEN, INC. (US) 2007-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100330030-A1 Vasculostatic Agents and Methods of Use Thereof RBP1, RBP4, VCAM1 PIK3CG 2378/4885ALDH1A1 745/4885USP2 4011/4885
US-20070208019-A1 Vasculostatic agents and methods of use thereof RBP1, RBP4, VCAM1 PIK3CG 2378/4885ALDH1A1 745/4885USP2 4011/4885
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF RBP1, RBP4, VCAM1 PIK3CG 2378/4885ALDH1A1 745/4885USP2 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback